Description:
This phase I trial is to find out the possible side effects of pembrolizumab and radiation
therapy before and during surgery in treating patients with head and neck squamous cell
cancer that remains despite treatment (persistent) or has come back (recurrent).
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Radiation therapy uses high energy x-rays or protons to kill tumor cells and shrink
tumors. Giving pembrolizumab and radiation therapy before and during surgery may kill more
tumor cells.
Title
- Brief Title: Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer
- Official Title: A Single-Institution, Randomized Pilot Study Study of Clinical and Immune Effects of Pembrolizumab and Peri-Operative Radiation in Combination With Salvage Surgery and Intraoperative Radiation in Patients With Persistent or Recurrent Head and Neck Squamous Cell Carcinoma
Clinical Trial IDs
- ORG STUDY ID:
OSU-20297
- SECONDARY ID:
NCI-2021-00036
- NCT ID:
NCT04754321
Conditions
- Head and Neck Carcinoma of Unknown Primary
- Locally Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Oral Cavity Squamous Cell Carcinoma
- Recurrent Pharyngeal Squamous Cell Carcinoma
- Resectable Head and Neck Squamous Cell Carcinoma
Interventions
| Drug | Synonyms | Arms |
|---|
| Pembrolizumab | Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Arm A (pembrolizumab, salvage surgery, IORT) |
Purpose
This phase I trial is to find out the possible side effects of pembrolizumab and radiation
therapy before and during surgery in treating patients with head and neck squamous cell
cancer that remains despite treatment (persistent) or has come back (recurrent).
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Radiation therapy uses high energy x-rays or protons to kill tumor cells and shrink
tumors. Giving pembrolizumab and radiation therapy before and during surgery may kill more
tumor cells.
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the potential toxicity of immunotherapy and preoperative radiation combined
with intra-operative radiation in patients with recurrent or persistent head and neck
squamous cell carcinoma (HNSCC).
SECONDARY OBJECTIVES:
I. To evaluate the clinical efficacy, measured as a locoregional control rate (LCR) and
progression-free survival (PFS), of immunotherapy and preoperative radiation combined with
intra-operative radiation in patients with recurrent or persistent HNSCC.
II. To evaluate the pre-operative radiation dose effect (0 Gy, 2 Gy X 2, 8 Gy X 2) on
anti-tumor immune response in the setting of immunotherapy in patients with recurrent or
persistent HNSCC.
III. To evaluate the radiation dose effect (0 Gy, 2 Gy X 2, 8 Gy X 2) on the expression of
the deoxyribonucleic acid (DNA) exonuclease Trex1.
IV. To compare the overall survival (OS) of pembrolizumab and pre-operative external beam
radiation therapy (EBRT) plus intraoperative radiation therapy (IORT) in subjects with
recurrent or persistent HNSCC.
V. To assess the overall safety and tolerability of pembrolizumab and pre-operative EBRT and
IORT plus post-operative pembrolizumab versus pre-operative pembrolizumab plus IORT and
post-operative pembrolizumab in subjects with with recurrent or persistent HNSCC.
VI. To evaluate whether PD-L1 expression is a predictive biomarker for LCR and PFS.
VII. To evaluate whether TNF-alpha expression is a predictive biomarker for LCR and PFS.
VIII. To evaluate whether NFkappaB expression is a predictive biomarker for LCR and PFS.
IX. To evaluate whether tumor mutational burden is predictive of immunotherapy response.
X. To evaluate the Health Related Quality of Life (HRQoL) as assessed by European
Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire -
Core 30 (QLQ-C30).
EXPLORATORY OBJECTIVES:
I. To evaluate associations between gene expression status of tumor samples and clinical
efficacy (LRC, PFS and overall survival [OS]).
II. To evaluate whether mutational burden is a predictive biomarker for LCR and PFS.
III. To explore potential biomarkers associated with clinical efficacy (LRC, PFS, and OS) by
analyzing circulating tumor DNA quantitative load with polymerase chain reaction (PCR),
chemokines/cytokines and immune cells (e.g. CD8+ T cells, regulatory T cells [Tregs], myeloid
derived suppressor cells [MDSCs]) with FACS in blood, tumor tissue and correlating those with
clinical outcomes.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive pembrolizumab intravenously (IV) on day 1 of week 1, and undergo
salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3
weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity.
Patients also undergo intraoperative radiation therapy (IORT) for 1 fraction during week 9.
Treatment with pembrolizumab may continue beyond initial progression per
investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
ARM B: Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2
fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during
week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses
in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT
for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial
progression per investigator-assessed clinical benefit and if the patient is tolerating
pembrolizumab.
ARM C: Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2
fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during
week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses
in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT
for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial
progression per investigator-assessed clinical benefit and if the patient is tolerating
pembrolizumab.
After completion of study treatment, patients are followed up at 90 and 180 days, then every
90 weeks for 24 months, and then every 6 months up to year 5.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Arm A (pembrolizumab, salvage surgery, IORT) | Experimental | Patients receive pembrolizumab IV on day 1 of week 1, and undergo salvage surgery during week 4. Beginning week 8, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 9. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab. | |
| Arm B (pembrolizumab, EBRT, salvage surgery, IORT) | Experimental | Patients receive pembrolizumab IV on day 1 of week 1, and undergo low dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab. | |
| Arm C (pembrolizumab, EBRT, salvage surgery, IORT) | Experimental | Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab. | |
Eligibility Criteria
Inclusion Criteria:
- Pathologically confirmed either persistent and/ or locoregionally recurrent HNSCC of
oral cavity, pharynx, larynx, unknown primary head and neck (H&N) squamous cell
carcinoma
- Resectable disease as determined by the surgeon and team
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2
- At least 18 years of age
- Adequate hematologic, renal, and hepatic function
- Must have at least 2 week washout period from prior therapy
- Willingness and ability to provide informed consent
- Negative pregnancy test for females of reproductive potential
- Patients who plan to or have undergone therapy for their cancer, such as surgery
and/or chemotherapy and/or radiotherapy and recurred
- Disease measurable by computed tomography (CT) or magnetic resonance imaging (MRI)
- Prior chemotherapy will be allowed
- Prior radiation therapy will be allowed
- Tumor tissue from resected site of disease must be provided for biomarker analyses, in
addition to urine and blood sample as scheduled per protocol
- White blood cell (WBC) >= 2000/uL (obtained within 14 days of randomization)
- Neutrophils >= 1500/uL (obtained within 14 days of randomization)
- Platelets >= 100 x10^3/uL (obtained within 14 days of randomization)
- Hemoglobin > 9.0 g/dL (obtained within 14 days of randomization)
- Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine
clearance (CrCl) >= 40 mL/min (Cockcroft and Gault or Wright formula may be used
according to local practice) (obtained within 14 days of randomization)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
(obtained within 14 days of randomization)
- Total Bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have
total bilirubin < 3.0 mg/dL) (obtained within 14 days of randomization)
- Women of childbearing potential (WOCBP) must use appropriate method(s) of
contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30
days plus the time required for nivolumab to undergo five half-lives) after the last
dose of nivolumab
- Women of childbearing potential must have a negative serum or urine pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin
[HCG])
- Men who are sexually active with WOCBP must use any contraceptive method with a
failure rate of less than 1% per year. Men who are sexually active with WOCBP will be
instructed to adhere to contraception for a period of 31 weeks after the last dose of
investigational product
Exclusion Criteria:
- Requirement of immunosuppressive therapy within 14 days of randomization
- Salivary gland carcinomas, lip carcinoma, adenocarcinoma of the skin
- Prior use of immune checkpoint blockade agent
- History of human immunodeficiency virus (HIV), hepatitis B, C: Participants who test
positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus
ribonucleic acid (HCV antibody) indicating acute or chronic infection, those who test
positive for human immunodeficiency virus (HIV) or have known acquired
immunodeficiency syndrome (AIDS)
- Unresectable disease, as determined by the surgeon and team
- Subjects with history of grade 3 toxicity with prior immunotherapy
- Patients with untreated brain metastasis/es
- Subjects with active, known, or suspected autoimmune disease with the exception of
skin diseases that do not require systemic treatment (such as alopecia) and type I
diabetes
- Breastfeeding women
- Additional prior malignancy within the previous 3 years (treated or untreated, except
for skin carcinomas treated with excision alone and carcinoma in situ of the cervix)
- Palliative radiotherapy less than 14 days prior to first dose of study drug
- Any history of hypersensitivity to any of the trial medications or solutions they are
mixed into
- Poorly controlled or serious medical or psychiatric illness likely to interfere with
participation and/or compliance in this clinical trial
- Prisoners or subjects who are involuntarily incarcerated
- Patients not available for follow-up/future contact
- Note: Patients on this protocol are not excluded from participation in other clinical
trials
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Incidence of adverse events |
| Time Frame: | Up to 100 days after last dose of study drug |
| Safety Issue: | |
| Description: | Evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. Summarized by treatment group. All on-study adverse events (AEs), treatment-related AEs, serious (S)AEs, and treatment-related SAEs will be tabulated using worst grade per NCI CTCAE version 4.0 criteria by system organ class and preferred term. On-study lab parameters including hematology, chemistry, liver function, and renal function will also be summarized using worst grade NCI CTCAE v 4.0 criteria. Toxicity will be measured as the rate of grade 3 and 4 adverse events and will be calculated through using the exact binomial distribution method with a 2- sided 95% confidence interval. |
Secondary Outcome Measures
| Measure: | Objective-response rate (ORR) |
| Time Frame: | Up to 5 years |
| Safety Issue: | |
| Description: | ORR including complete response rate, partial response rate, and stable disease rate will be calculated using the exact binomial distribution method with a 2- sided 95% confidence interval among patients who obtain a least one dose of study drug. |
| Measure: | Local control rate |
| Time Frame: | From the first day of therapy to the occurrence of a local and/or regional recurrence (whichever comes first), and death from any cause other than distant metastasis, assessed up to 24 months |
| Safety Issue: | |
| Description: | Analyses will be conducted using Kaplan-Meier method for each arm. The hazard ratio and corresponding two-sided 95% CI will be estimated using a Cox proportional hazards model, with treatment group as a single covariate. |
| Measure: | Overall survival |
| Time Frame: | Up to 5 years |
| Safety Issue: | |
| Description: | Analyses will be conducted using Kaplan-Meier method for each arm. The hazard ratio and corresponding two-sided 95% CI will be estimated using a Cox proportional hazards model, with treatment group as a single covariate. |
| Measure: | Progression-free survival (PFS) |
| Time Frame: | From the first day of the therapy to the appearance of local or regional recurrence, distant metastases, secondary primary cancer or death from any cause, assessed up to 24 months |
| Safety Issue: | |
| Description: | Analyses will be conducted using Kaplan-Meier method for each arm. The PFS medians with 95% confidence intervals (CIs), and PFS at 6, 12, and 24 months with 95% CIs will be estimated a two-sided log-rank test. The hazard ratio and corresponding two-sided 95% CI will be estimated using a Cox proportional hazards model, with treatment group as a single covariate, stratified by the above factors. |
| Measure: | PD-L1 expression |
| Time Frame: | Up to 5 years |
| Safety Issue: | |
| Description: | A Cox proportional hazards model will be used to test the interaction between PD-L1 expression (positive vs negative) and treatment arm. |
Details
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Not yet recruiting |
| Lead Sponsor: | Ohio State University Comprehensive Cancer Center |
Last Updated
February 15, 2021
